智通财经网·2025-08-21 02:08Core Viewpoint - 康希诺生物 reported a significant improvement in its financial performance for the first half of 2025, with a notable increase in revenue and a reduction in losses, indicating a positive trend in its business operations [1] Financial Performance - The company achieved a revenue of approximately 374 million yuan, representing a year-on-year growth of 31.1% [1] - Research and development expenses decreased by 20.5% to about 148 million yuan [1] - The net loss attributable to owners narrowed to 13.485 million yuan, a reduction of 94.02% compared to the previous year [1] - The loss per share was reported at 0.05 yuan [1] Product Development and Market Performance - 康希诺生物 continued to advance the commercialization of its meningococcal conjugate vaccine, with the product successfully launched in China's mid-to-high-end vaccine market [1] - The sales revenue from the meningococcal conjugate vaccine reached approximately 364 million yuan, marking a year-on-year increase of 38.4%, contributing to stable revenue growth for the company [1] R&D Efficiency - The reduction in R&D expenses was attributed to the company's focus on integrating research resources and leveraging potential synergies across different pipelines, which enhanced research efficiency while lowering costs [1]